Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?

J Clin Oncol. 2023 Feb 20;41(6):1172-1175. doi: 10.1200/JCO.22.02278. Epub 2023 Jan 9.

Authors

Ziming Li¹, Shun Lu¹

Affiliation

¹ Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

PMID: 36623229
DOI: 10.1200/JCO.22.02278

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Ipilimumab / therapeutic use
Lung Neoplasms* / drug therapy
Nivolumab / therapeutic use

Substances

Nivolumab
Ipilimumab
Antibodies, Monoclonal